Incyte (INCY) Q4 Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Incyte Reports 2017 Fourth-Quarter and Year-End Financial Results, Provides 2018 Financial Guidance and Updates on Key Clinical Programs
February 15, 2018 7:00 AM ESTTotal revenues $444 million (+36%) in Q4 2017 and $1.54 billion (+39%) in FY 2017 Jakafi® (ruxolitinib) revenues $302 million (+27%) in Q4 2017 and $1.13 billion (+33%) in FY 2017; FY 2018 guidance $1.35-1.40 billion Significant progress in clinical development during 2017; portfolio now includes six later-stage product candidates
Conference Call and Webcast Scheduled Today at 8:00 a.m. ET
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (Nasdaq: INCY) today reports 2017 fourth-quarter and year-end financial results, highlighting both strong growth in total revenue and the significant progress being made... More
